This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Shaikh T , Li T , Murphy CT , Zaorsky NG , Bleicher RJ , Sigurdson ER , Carlson R , Hayes SB , Anderson P
Importance of Surgical Margin Status in Ductal Carcinoma In Situ
Clin Breast Cancer. 2016 Aug;16(4) :312-8
PMID: 26952595 URL: http://www.ncbi.nlm.nih.gov/pubmed/26952595
AbstractBACKGROUND: The purpose of the study was to identify the effect of final surgical margin (SM) status and re-excision on outcomes in patients with ductal carcinoma in situ (DCIS) who underwent breast conservation therapy (BCT). PATIENTS AND METHODS: The study population consisted of women diagnosed with DCIS who underwent BCT between 1989 and 2014. All women received adjuvant whole breast radiation and a boost. The primary end point was local control (LC). Final SMs were defined according to margin width: negative SM was defined as > 2 mm, close SM was defined as > 0 to </= 2 mm, and a positive SM was defined as tumor on ink. The Cox proportional hazards model was used to determine predictors of outcomes on multivariable analysis. Actuarial incidence of LC was estimated using the Kaplan-Meier method. RESULTS: A total of 498 patients were included; 400 patients had a final negative SM, 87 had a close SM, and 11 had a positive SM. A total of 172 patients received adjuvant hormonal therapy, 265 patients required >/= 1 re-excision. Patients with positive or close SMs were more likely to receive a radiation dose > 60 Gy (P < .001) and undergo re-excision (P < .01). The 10-year LC rates were not significantly different between patients with a negative (93.5%), close (91.8%), or positive (100%) SM (P = .57). There was no difference in LC in patients who underwent re-excision for initial close or positive SMs (P = .55). CONCLUSION: This single-institution experience showed that risks of local recurrence remain poorly characterized. Re-excision and whole breast radiation with boost resulted in excellent LC for women with DCIS. Trials aimed at personalized deintensified local therapy are warranted.
NotesShaikh, Talha Li, Tianyu Murphy, Colin T Zaorsky, Nicholas G Bleicher, Richard J Sigurdson, Elin R Carlson, Robert Hayes, Shelly B Anderson, Penny eng 2016/03/10 06:00 Clin Breast Cancer. 2016 Aug;16(4):312-8. doi: 10.1016/j.clbc.2016.02.002. Epub 2016 Feb 12.